MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure furt...
Saved in:
Main Authors | , , , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
04.10.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed. |
---|---|
Bibliography: | Application Number: EP20210827762 |